Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, February 22, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Serge Belanger Upgraded (BCRX) to Strong Buy and Held Target at $14 on, Feb 22nd, 2023
Serge Belanger of Needham, Upgraded "BioCryst Pharmaceuticals, Inc." (BCRX) to Strong Buy and Held Target at $14 on, Feb 22nd, 2023.
Serge has made no other calls on BCRX in the last 4 months.
There are 2 other peers that have a rating on BCRX. Out of the 2 peers that are also analyzing BCRX, 1 agrees with Serge's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $13 on, Wednesday, November 2nd, 2022
This is the rating of the analyst that currently disagrees with Serge
- Liisa Bayko of "Evercore ISI Group" Upgraded from Hold to Buy and Held Target at $16 on, Wednesday, November 2nd, 2022
